| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
|
JAMA
|
2004
|
7.32
|
|
2
|
Predictors of hospital mortality in the global registry of acute coronary events.
|
Arch Intern Med
|
2003
|
7.25
|
|
3
|
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
|
Gastroenterology
|
2010
|
6.14
|
|
4
|
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).
|
BMJ
|
2006
|
4.18
|
|
5
|
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery.
|
JAMA
|
2011
|
3.97
|
|
6
|
Predictors of mortality and morbidity in patients with chronic heart failure.
|
Eur Heart J
|
2005
|
3.09
|
|
7
|
International variation in and factors associated with hospital readmission after myocardial infarction.
|
JAMA
|
2012
|
2.75
|
|
8
|
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
|
Lancet
|
2009
|
2.13
|
|
9
|
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.
|
Am J Med
|
2005
|
2.08
|
|
10
|
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
|
Stroke
|
2013
|
1.99
|
|
11
|
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
|
Am J Cardiol
|
2005
|
1.96
|
|
12
|
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.
|
Circulation
|
2002
|
1.88
|
|
13
|
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
|
JAMA
|
2012
|
1.87
|
|
14
|
Can one assess whether missing data are missing at random in medical studies?
|
Stat Methods Med Res
|
2006
|
1.85
|
|
15
|
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
|
Circulation
|
2012
|
1.84
|
|
16
|
Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.
|
JAMA
|
2009
|
1.80
|
|
17
|
Representation of women in randomized clinical trials of cardiovascular disease prevention.
|
Circ Cardiovasc Qual Outcomes
|
2010
|
1.76
|
|
18
|
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
|
J Card Fail
|
2006
|
1.72
|
|
19
|
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease.
|
Am Heart J
|
2012
|
1.59
|
|
20
|
The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction.
|
Crit Care Med
|
2013
|
1.52
|
|
21
|
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
|
Crit Care Med
|
2011
|
1.50
|
|
22
|
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
|
Eur Heart J
|
2009
|
1.48
|
|
23
|
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
|
Heart Rhythm
|
2006
|
1.41
|
|
24
|
Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
|
J Am Coll Cardiol
|
2006
|
1.39
|
|
25
|
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
1.37
|
|
26
|
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2011
|
1.33
|
|
27
|
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Eur J Heart Fail
|
2009
|
1.13
|
|
28
|
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
|
Int J Cardiol
|
2012
|
1.12
|
|
29
|
Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial.
|
Arch Intern Med
|
2011
|
1.06
|
|
30
|
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction.
|
Am J Med
|
2006
|
1.04
|
|
31
|
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
|
JACC Cardiovasc Interv
|
2008
|
1.02
|
|
32
|
Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome.
|
Am Heart J
|
2004
|
0.99
|
|
33
|
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction.
|
Eur Heart J
|
2006
|
0.89
|
|
34
|
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
|
Am Heart J
|
2006
|
0.89
|
|
35
|
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
|
Biostatistics
|
2010
|
0.89
|
|
36
|
Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery.
|
Am Heart J
|
2009
|
0.89
|
|
37
|
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).
|
Am J Cardiol
|
2006
|
0.87
|
|
38
|
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury.
|
Am J Physiol Heart Circ Physiol
|
2013
|
0.86
|
|
39
|
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
|
Am Heart J
|
2002
|
0.86
|
|
40
|
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.
|
Am J Cardiol
|
2011
|
0.85
|
|
41
|
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
42
|
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.
|
Can J Cardiol
|
2004
|
0.83
|
|
43
|
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
|
Catheter Cardiovasc Interv
|
2007
|
0.82
|
|
44
|
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
|
J Gen Intern Med
|
2008
|
0.82
|
|
45
|
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy.
|
Am J Med
|
2011
|
0.82
|
|
46
|
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
|
Catheter Cardiovasc Interv
|
2010
|
0.81
|
|
47
|
Mobile cardiac catheterization laboratories increase use of cardiac care in women and African Americans.
|
Am Heart J
|
2007
|
0.81
|
|
48
|
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock.
|
Am J Cardiol
|
2007
|
0.80
|
|
49
|
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
|
Am Heart J
|
2010
|
0.80
|
|
50
|
Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population.
|
Am Heart J
|
2011
|
0.80
|
|
51
|
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
|
JAMA
|
2005
|
0.80
|
|
52
|
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
53
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
54
|
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2005
|
0.78
|
|
55
|
Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.
|
Can J Cardiol
|
2009
|
0.78
|
|
56
|
Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.
|
J Invasive Cardiol
|
2004
|
0.77
|
|
57
|
Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
|
Am J Cardiol
|
2004
|
0.77
|
|
58
|
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
|
Am Heart J
|
2013
|
0.76
|
|
59
|
Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes.
|
JACC Cardiovasc Interv
|
2012
|
0.75
|
|
60
|
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
|
Stroke
|
2013
|
0.75
|
|
61
|
Challenges and solutions to pre- and post-randomization subgroup analyses.
|
Curr Cardiol Rep
|
2014
|
0.75
|
|
62
|
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
|
J Interv Cardiol
|
2013
|
0.75
|
|
63
|
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
|
Am J Cardiol
|
2009
|
0.75
|
|
64
|
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb.
|
Eur Heart J
|
2008
|
0.75
|
|
65
|
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
|
J Interv Cardiol
|
2007
|
0.75
|
|
66
|
Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2010
|
0.75
|
|
67
|
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.
|
Am Heart J
|
2012
|
0.75
|
|
68
|
Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk.
|
Am Heart J
|
2011
|
0.75
|
|
69
|
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
|
Am Heart J
|
2007
|
0.75
|
|
70
|
A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial.
|
Am Heart J
|
2012
|
0.75
|
|
71
|
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.
|
Clin Cardiol
|
2014
|
0.75
|
|
72
|
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.75
|
|
73
|
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.
|
Am J Cardiol
|
2005
|
0.75
|